TY - JOUR
T1 - High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens
AU - Reissig, Chad J.
AU - Carter, Lawrence P.
AU - Johnson, Matthew W.
AU - Mintzer, Miriam Z.
AU - Klinedinst, Margaret A.
AU - Griffiths, Roland R.
N1 - Funding Information:
Acknowledgments This research was supported by NIDA grant DA003889. We would like to thank Mary Cosimano, M.S.W., Lilian Salinas, and Jenna Cohen for serving as assistant session monitors. We thank John Yingling for technical assistance, Barine Duman Majew-ska, J.D. for database programming, and Linda Felch for statistical assistance. The study was conducted in compliance with United States laws.
PY - 2012/9
Y1 - 2012/9
N2 - Rationale: Although reports of dextromethorphan (DXM) abuse have increased recently, few studies have examined the effects of high doses of DXM. Objective: This study in humans evaluated the effects of supratherapeutic doses of DXM and triazolam. Methods: Single, acute oral doses of DXM (100, 200, 300, 400, 500, 600, 700, and 800 mg/70 kg), triazolam (0.25 and 0.5 mg/70 kg), and placebo were administered to 12 healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Subjective, behavioral, and physiological effects were assessed repeatedly after drug administration for 6 h. Results: Triazolam produced dose-related increases in subject-rated sedation, observer-rated sedation, and behavioral impairment. DXM produced a profile of dose-related physiological and subjective effects differing from triazolam. DXM effects included increases in blood pressure, heart rate, and emesis; increases in observer-rated effects typical of classic hallucinogens (e.g., distance from reality, visual effects with eyes open and closed, joy, anxiety); and participant ratings of stimulation (e.g., jittery, nervous), somatic effects (e.g., tingling, headache), perceptual changes, end-of-session drug liking, and mystical-type experience. After 400 mg/70 kg DXM, 11 of 12 participants indicated on a pharmacological class questionnaire that they thought they had received a classic hallucinogen (e.g., psilocybin). Drug effects resolved without significant adverse effects by the end of the session. In a 1-month follow-up, volunteers attributed increased spirituality and positive changes in attitudes, moods, and behavior to the session experiences. Conclusions: High doses of DXM produced effects distinct from triazolam and had characteristics that were similar to the classic hallucinogen psilocybin.
AB - Rationale: Although reports of dextromethorphan (DXM) abuse have increased recently, few studies have examined the effects of high doses of DXM. Objective: This study in humans evaluated the effects of supratherapeutic doses of DXM and triazolam. Methods: Single, acute oral doses of DXM (100, 200, 300, 400, 500, 600, 700, and 800 mg/70 kg), triazolam (0.25 and 0.5 mg/70 kg), and placebo were administered to 12 healthy volunteers with histories of hallucinogen use, under double-blind conditions, using an ascending dose run-up design. Subjective, behavioral, and physiological effects were assessed repeatedly after drug administration for 6 h. Results: Triazolam produced dose-related increases in subject-rated sedation, observer-rated sedation, and behavioral impairment. DXM produced a profile of dose-related physiological and subjective effects differing from triazolam. DXM effects included increases in blood pressure, heart rate, and emesis; increases in observer-rated effects typical of classic hallucinogens (e.g., distance from reality, visual effects with eyes open and closed, joy, anxiety); and participant ratings of stimulation (e.g., jittery, nervous), somatic effects (e.g., tingling, headache), perceptual changes, end-of-session drug liking, and mystical-type experience. After 400 mg/70 kg DXM, 11 of 12 participants indicated on a pharmacological class questionnaire that they thought they had received a classic hallucinogen (e.g., psilocybin). Drug effects resolved without significant adverse effects by the end of the session. In a 1-month follow-up, volunteers attributed increased spirituality and positive changes in attitudes, moods, and behavior to the session experiences. Conclusions: High doses of DXM produced effects distinct from triazolam and had characteristics that were similar to the classic hallucinogen psilocybin.
KW - Dextromethorphan
KW - Dose effects
KW - Drug abuse
KW - Entheogen
KW - Hallucinogen
KW - Humans
KW - Mystical experience
KW - Psychedelic
KW - Subjective effects
KW - Triazolam
UR - http://www.scopus.com/inward/record.url?scp=84859515151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84859515151&partnerID=8YFLogxK
U2 - 10.1007/s00213-012-2680-6
DO - 10.1007/s00213-012-2680-6
M3 - Review article
C2 - 22526529
AN - SCOPUS:84859515151
SN - 0033-3158
VL - 223
SP - 1
EP - 15
JO - Psychopharmacology
JF - Psychopharmacology
IS - 1
ER -